Salma Haj-Yahia; Arijit Nandi; Raphael I. Benhamou
Expert Opin. Drug Discov., 2023, 18(8), 929-942
https://doi.org/10.1080/17460441.2023.2224960

Abstract

RNA structural motifs can serve as recognition sites for proteins or regulatory elements. Notably, these specific RNA shapes are directly related to many diseases. Targeting specific RNA motifs using small molecules is an emerging domain of study within the area of drug discovery. Targeted degradation strategies are a relatively modern technology in drug discovery, with important clinical and therapeutic outcomes. These approaches involve using small molecules to selectively degrade specific biomacromolecules associated with a disease.”Ribonuclease-Targeting Chimeras” (RiboTaCs) represent a promising type of targeted degradation strategy because of their ability to selectively degrade structured RNA targets.